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A B S T R A C T
Objectives: The aim of this study was to investigate the association between detention experience and
hepatitis C virus (HCV) status, the role of duration and frequency of detention, and whether risk
behaviours practiced in detention could explain an observed increase in risk.
Methods: Current drug injectors (injecting in the last 12 months) were recruited to participate in a sero-
behavioural, cross-sectional survey using respondent-driven sampling in eight German cities during the
years 2011–2014. Using multivariable logistic regression, the association between HCV status and
reported detention experience was investigated.
Results: A total of 1998 participants were included in the analysis. Of these, 19.9% reported no detention
experience, 28.6% short and rare experience (3.5 years in total, 3 times), 12.1% short but frequent
experience, 7.1% long but rare experience, and 32.4% long and frequent experience. After correcting for
HCV risk factors, the association between detention experience and HCV status remained statistically
significant. By adjusting the model for intramural risk behaviours, the odds ratios of detention experience
were reduced but remained significant.
Conclusions: The proportion of people who inject drugs positive for HCV increased with both frequency
and duration of their detention experience. As intramural risk behaviours could not fully explain this
increase, it appears that transfers between community and custody may confer additional risks.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hepatitis C (HCV) is a viral, blood-borne infection that becomes
chronic in eight out of 10 cases, with the development of liver
cirrhosis or liver cancer as possible long-term consequences (Te
and Jensen, 2010). The use of contaminated injection equipment is
an important mode of transmission, making the group of people
who inject drugs (PWID) particularly vulnerable to HCV. In most* Corresponding author.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).countries, this group is disproportionately affected by the
infection, and the global HCV prevalence among PWID has recently
been estimated to be 52% (Degenhardt et al., 2016).
Prison experience is common among PWID, due to both drug-
related crime and to acquisitive offending (Pierce et al., 2017).
Individuals with a history of injecting drug use are overrepresented
in prison populations across Europe and other developed countries
(EMCDDA, 2012; Australian Institute of Health and Welfare, 2013).
In Germany, it is estimated that 22–30% of sentenced inmates have
a history of injecting drug use (Schulte et al., 2009; Eckert, 2008).
Despite prisons being highly controlled settings, drugs fre-
quently find their way inside, making it possible for incarcerated
PWID to continue their drug use. In the only existing, representa-
tive study of the German prison population from 2007, 33% of
PWID reported injecting in prison (Eckert, 2008). Similar rates
have been found in countries like Australia, Denmark, and Greece;ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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reported at significantly higher rates (Dolan et al., 2010; Snow
et al., 2014; Luciani et al., 2014; Christensen et al., 2000; Malliori
et al., 1998). To a certain extent, prisons also serve as a place where
injecting drug use is initiated (Eckert, 2008; Taylor et al., 1995;
Butler et al., 2004).
Access to sterile injecting equipment, on the other hand, is very
limited, as clean needles, syringes, and other injecting parapher-
nalia are rarely available. Despite the recommendations of the
United Nations Office on Drugs and Crime and the World Health
Organization to provide needle exchange programmes (NSP) for
inmates, merely eight countries worldwide offered NSP in at least
one prison in 2016 (Harm Reduction International, 2016; UNODC/
ILO/UNDP/WHO/UNAIDS, 2013). To date, NSP is available in only
one (female) prison in Germany. Difficulties accessing sterile
injecting equipment lead to increased unsafe use, as the
equipment must frequently be shared between inmates (Dolan
et al., 2010; Luciani et al., 2014; Malliori et al., 1998; Taylor et al.,
1995; Schäffler, 2012; O’Sullivan et al., 2003; Haber et al.,1999). In a
paper on behavioural change amongst drug injectors in Scottish
prisons, Shewan et al. described how the number of PWID sharing
injecting equipment went up from 24% prior to imprisonment to
76% during imprisonment (Shewan et al., 1994).
At the same time, prison populations, especially those with a
history of injecting drug use, often have a high prevalence of HCV. A
meta-analysis of detained populations from 2013 estimated that
two-thirds of detainees with a history of drug injection were
positive for HCV antibodies (Larney et al., 2013). High HCV
prevalence and multiple sharing among prisoners thus result in a
high risk of infection. The same meta-analysis estimated the
incidence rate among prisoners with a history of drug injection to
be 16.4 per 100 person-years (Larney et al., 2013). The results of
another meta-analysis by Stone et al. also suggest that recent
incarceration among PWID is associated with a substantial
increase in HCV acquisition risk (Stone et al., 2018).
Studies of PWID in the community have found previous
imprisonment, multiple imprisonments, and the duration of
imprisonment all to be associated with HCV infection; however,
only one of these aspects is usually considered at a time (Macalino
et al., 2016). Less is known about how the frequency and the
duration of imprisonment each affect the risk of HCV. Thus, using
data from a large sero-behavioural survey of PWID in Germany, this
analysis was performed with the aim of investigating (1) the
association between detention experience and HCV status, (2) the
role of the duration and frequency of detention, and (3) whether




A multicenter sero-behavioural survey was conducted in eight
German cities between 2011 and 2014. Participants were recruited
using respondent-driven sampling over a period of 8–10 weeks in
each city. Study participation was reimbursed with s10 and
another s5 for each successful peer-recruitment, with a maximum
of three recruitments. Eligibility criteria for study inclusion were
injecting drug use in the past 12 months, drug consumption in the
surveyed city, and a minimum age of 16 years. All participants were
asked to provide informed consent before being enrolled into the
study.
Enrolled participants were interviewed face-to-face about their
demographic characteristics, drugs used, injecting behaviour,
sexual behaviour, detention experience, history of HIV, hepatitis
B virus (HBV), and HCV testing, health status, and knowledgerelated to HIV, hepatitis B, and hepatitis C. An interview typically
lasted 30–45 minutes. Each participant was also asked to provide a
capillary blood sample on filter paper (i.e., dried blood spots),
which was sent to the laboratory for analysis of serological and
molecular markers for HBV, HCV, and HIV. If desired, participants
could later pick up their test results. Ethical approval for the study
was granted by the ethics committee of the Charité University of
Medicine, Berlin.
A detailed description of the study protocol has been published
elsewhere (Zimmermann et al., 2014).
Measures
The outcome variable used in this analysis was HCV status
(negative/positive). A positive HCV status was defined as testing
positive for antibodies, RNA, or both. Subsequently a negative HCV
status was defined as having a negative result with both tests. Test
results for both HCV antibodies and HCV RNA were available for all
participants. The variable of interest in this analysis was detention
experience. Having detention experience was defined as having
ever been at least once in any of the following: juvenile arrest/
prison, pre-trial custody, prison, forensic commitment (i.e.,
detention in a clinic for forensic psychiatric care, following a
criminal conviction). Due to the way the data were collected, it was
not possible to consider the various forms of detention separately.
The variable was divided into five categories: none, short and rare,
short but frequent, long but rare, and long and frequent. The
duration (short vs. long) contained in the variable of interest was
defined as the total duration of all detentions, where short was up
to 42 months (3.5 years) and long was 43 months or longer. The
frequency (rare vs. frequent) contained in the variable of interest
was defined as the sum of all detentions, where rare was three
times or less and frequent was four times or more. The two cut-off
values were based on the median total detention duration and
median detention frequency.
Risk factors for HCV previously described in the literature were
identified in the dataset and those considered as possible
confounders of the relationship between detention experience
and HCV status were selected for analysis. The following variables
were selected: age (<25 years, 25–39 years, 40 years), sex (male,
female), region of birth (Germany, Western Europe, Central Europe,
Former Soviet Union, Middle East, other), ever having been
homeless (no, yes), duration of injecting drug use (2 years, 3–
10 years, >10 years), typical number of injections on an average
injection day (1, 2–4, 5), and ever had a non-professional tattoo/
piercing while not in detention (no, yes). Known in-detention risk
behaviours for HCV infection were also identified and those for
which data were available were selected for the last step of the
analysis: ever injected drugs in detention (no, yes), ever had a non-
professional tattoo/piercing while in detention (no, yes).
If a question was answered with either “I don’t remember” or “I
don’t want to answer”, the response was re-coded as missing.
Participants with incomplete data on detention experience and
those in the stage of seroconversion (HCV antibody-negative, HCV
RNA-positive) with last detention experience more than 12
months ago were excluded from the analysis.
Data analysis
A descriptive analysis was performed, generating counts and
frequencies for all variables, as well as calculating the HCV
seroprevalence for each variable category. To investigate the
univariable associations between HCV status and each of the
variables, logistic regression was used, reporting the odds ratio
(OR) and 95% confidence interval (CI). As a next step, a
multivariable model was built using stepwise forward selection.
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interest), as well as age, sex, and study site. These variables were
locked into the model throughout the selection procedure,
regardless of their significance. The remaining variables were
added in order of significance from the univariable analysis
(p < 0.2). The model improvement was tested using the likelihood
ratio test (p < 0.05). A backward stepwise elimination was also
performed with the same set of variables. The same variables were
locked in as in the forward selection and the ‘p-value to remove’
was set at 0.2. Upon completing the variable selection for the
multivariable model, interactions considered meaningful a priori
between detention experience and selected confounders were
examined. The interaction terms were added to the multivariable
model one by one, checking for significant improvement using the
likelihood ratio test (p < 0.05). As a final step, the in-detention risk
behaviour variables were added to the model in order to examine
how this affected the effect of detention experience.
Missing data were excluded when calculating percentages, and
list-wise deletion was applied in all logistic regression analyses
described. All statistical analyses were performed using Stata
version 13.1 for Windows (StataCorp LP).
Results
A total of 2077 participants were recruited for the study. Of
these, 63 (3.0%) had incomplete data on detention experience and
16 (0.8%) were in the stage of HCV seroconversion with last
reported detention experience more than 12 months ago and were
thus excluded, resulting in a study sample of 1998 participants.
Data were missing for 0.10–1.05% of observations, with the
exception of the variable ‘typical number of injections on anTable 1
Distribution of characteristics and behaviours of the study population.





Region of birth 
Ever homeless 
Duration of injecting drug use (years) 
Typical number of injections on an average injecting day 
Ever had non-professional tattoo/piercing while not in detention 
In-detention risk behaviour (N = 1998)
Ever injected drugs in detention 
Ever had non-professional tattoo/piercing while in detention 
HCV, hepatitis C virus.
a Category also includes never detained individuals.average injection day’ for which data were missing for 4.7%. Of the
individuals included in the analysis, 6.6% were younger than 25
years of age, 76.3% were male, and 22.2% were born outside of
Germany (Table 1). The most common substances consumed in the
last 30 days were heroin (74.7%), benzodiazepines (49.4%), and
cocaine (48.4%). The majority (70.9%) reported more than 10 years
of injecting drug use, most commonly injecting 2–4 times on an
average injecting day (55.6%).
One fifth (19.9%) of the participants reported not having any
detention experience, while 32.4% reported long and frequent and
28.6% short and rare detention experience. Short but frequent and
long but rare detention experience were less common (12.1% and
7.1%, respectively). Four hundred and seventy participants reported
ever having injected drugs while in detention, corresponding to
23.6% of the entire sample and to 29.4% of those reporting
detention experience. The proportion of participants who had ever
had a non-professional tattoo/piercing while in detention corre-
sponded to 26.5% of the entire sample and to 32.9% of those ever
detained. The proportion of participants reporting these risk
factors increased significantly with both total duration and
frequency of detention (Table 2). The overall HCV seroprevalence
in the sample was 64.7%.
HCV seroprevalence increased along with the duration and
frequency of detention experience, from 48.6% among those with
no experience to 79.1% among those with long and frequent
experience (Table 3). In the univariable analysis, all types of
detention experience were significantly associated with HCV
seropositivity: OR 1.35 (95% CI 1.04–1.74) for short and rare
experience, OR 2.09 (95% CI 1.50–2.91) for short but frequent
experience, OR 3.36 (95% CI 2.18–5.18) for long but









Short and rare 571 (28.6)
Short but frequent 241 (12.1)
Long but rare 142 (7.1)
Long and frequent 647 (32.4)
Germany 1553 (77.9)
Western Europe 67 (3.4)
Central Europe 80 (4.0)
Former Soviet Union 203 (10.2)

















Frequency of in-detention risk behaviours by type of detention experience.
Ever injected drugs in detention Ever had non-professional tattoo/piercing while in detention
No, n (%) Yes, n (%) p-Valuea No, n (%) Yes, n (%) p-Valuea
Detention experience
Short and rare 507 (89.3) 61 (10.7) 0.000 501 (88.7) 64 (11.3) 0.000
Short but frequent 191 (79.3) 50 (20.8) 188 (78.3) 52 (21.7)
Long but rare 92 (64.8) 50 (35.2) 87 (61.3) 55 (38.7)
Long and frequent 338 (52.2) 309 (47.8) 292 (45.3) 352 (54.7)
a Chi-square test.
Table 3
HCV seroprevalence by risk factor—univariable associations.
Characteristic or behaviour (N = 1998) HCV seropositive
n (%)
OR 95% CI
Detention experience None 193 (48.6) Reference
Short and rare 320 (56.0) 1.35 1.04–1.74
Short but frequent 160 (66.4) 2.09 1.50–2.91
Long but rare 108 (76.1) 3.36 2.18–5.18
Long and frequent 512 (79.1) 4.01 3.05–5.27
Age (years) <25 46 (34.9) Reference
25–39 609 (61.8) 3.02 2.06–4.42
40 637 (72.6) 4.94 3.35–7.28
Sex Male 982 (64.5) Reference
Female 309 (65.5) 1.04 0.84–1.30
Region of birth Germany 1004 (64.7) Reference
Western Europe 48 (71.6) 1.38 0.80–2.37
Central Europe 42 (52.5) 0.60 0.38–0.95
Former Soviet Union 150 (73.9) 1.55 1.11–2.15
Middle East 41 (56.2) 0.70 0.44–1.13
Other 7 (38.9) 0.35 0.13–0.90
Ever homeless No 415 (60.9) Reference
Yes 873 (66.6) 1.29 1.06–1.56
Duration of injecting drug use (years) 2 30 (26.8) Reference
3–10 243 (52.2) 2.98 1.89–4.70
>10 1015 (72.2) 7.11 4.61–10.98
Typical number of injections on an average injecting day 1 243 (54.5) Reference
2–4 710 (67.0) 1.70 1.36–2.13
5 290 (72.7) 2.22 1.67–2.97
Ever had non-professional tattoo/piercing while not in detention No 941 (63.9) Reference
Yes 342 (67.9) 1.19 0.96–1.48
In-detention risk behaviour (N = 1998)
Ever injected drugs in detention Noa 905 (59.3) Reference
Yes 387 (82.3) 3.19 2.47–4.14
Ever had non-professional tattoo/piercing while in detention Noa 885 (60.9) Reference
Yes 398 (76.1) 2.05 1.63–2.57
HCV, hepatitis C virus; OR, odds ratio; CI, confidence interval.
a Category also includes never detained individuals.
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with none. Other factors significantly associated with a positive
HCV status in the univariable analysis were age, region of birth,
ever being homeless, duration of injecting drug use, number of
injections on an average injecting day, and ever having had a non-
professional tattoo/piercing while not in detention. The two risk
behaviours specific to the detention setting were also significant-
ly associated with a positive HCV status: ever injected drugs in
detention with OR 3.19 (95% CI 2.47–4.14) and ever had a non-
professional tattoo/piercing while in detention with OR 2.05 (95%
CI 1.63–2.57).
In the multivariable analysis, both selection procedures
rendered the same model. Variables included in the final model
to correct for confounding effects on the association between
detention experience and HCV status were age, sex, region of birth,
duration of injecting drug use, typical number of injections on an
average injecting day, and having ever had a non-professional
tattoo/piercing while not in detention (see Table 4). None of the
tested interaction terms improved the model significantly.Correcting for these variables and study site did not lead to a
loss of significance of detention experience, which remained
associated with an increased risk of HCV with the following odds
ratios: OR 1.39 (95% CI 1.04–1.86) for short and rare experience, OR
2.08 (95% CI 1.43–3.02) for short but frequent experience, OR 3.32
(95% CI 2.04–5.37) for long but rare experience, and OR 3.80 (95% CI
2.73–5.28) for participants with long and frequent detention
experience, compared to those with none.
Adding the in-detention risk behaviours to the model, which
are known to mediate the relationship between detention
experience and HCV status as they are part of the causal pathway,
decreased the ORs of detention experience but did not lead to a loss
of significance. The ORs of detention experience in the model
including the in-detention risk behaviours were as follows: OR 1.31
(95% CI 0.97–1.76) for short and rare experience, OR 1.83 (95% CI
1.25–2.67) for short but frequent experience, OR 2.68 (95% CI 1.62–
4.42) for long but rare experience, and OR 2.80 (95% CI 1.92–4.09)
for long and frequent detention experience, compared to those
with none.
Table 4
Multivariable models excluding and including variables of in-detention risk behaviours.
Characteristic or behaviour Model excluding in-detention risk
behavioursa
Model including in-detention risk
behavioursa
OR 95% CI OR 95% CI
Detention experience None Reference Reference
Short and rare 1.39 1.04–1.86 1.31 0.97–1.76
Short but frequent 2.08 1.43–3.02 1.83 1.25–2.67
Long but rare 3.32 2.04–5.37 2.68 1.62–4.42
Long and frequent 3.80 2.73–5.28 2.80 1.92–4.09
Age (years) <25 Reference Reference
25–39 1.48 0.94–2.34 1.54 0.97–2.45
40 1.98 1.20–3.28 2.01 1.21–3.33
Sex Male Reference Reference
Female 1.75 1.34–2.28 1.75 1.34–2.28
Region of birth Germany Reference Reference
Western Europe 2.23 1.18–4.22 2.27 1.20–4.29
Central Europe 0.84 0.50–1.40 0.81 0.48–1.35
Former Soviet Union 2.69 1.82–3.98 2.77 1.86–4.13
Middle East 0.85 0.49–1.45 0.88 0.51–1.51
Other 0.31 0.11–0.91 0.31 0.10–0.90
Duration of injecting drug use (years) 2 Reference Reference
3–10 3.34 2.00–5.55 3.31 1.99–5.52
>10 5.01 3.04–8.27 4.76 2.88–7.85
Typical number of injections on an average injecting day 1 Reference Reference
2–4 1.68 1.31–2.16 1.64 1.27–2.11
5 2.36 1.70–3.27 2.25 1.62–3.12
Ever had non-professional tattoo/piercing while not in detention No Reference Reference
Yes 1.38 1.07–1.77 1.39 1.08–1.79
In-detention risk behaviour
Ever injected drugs in detention Nob Reference
Yes 1.78 1.30–2.44
Ever had non-professional tattoo/piercing while in detention Nob Reference
Yes 1.16 0.86–1.56
OR, odds ratio; CI, confidence interval.
a Model adjusted for study site.
b Category also includes never detained individuals.
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Main findings
This analysis found an association between detention experi-
ence and HCV exposure in a sample of active injecting drug users.
Individuals with longer and more frequent detention experience
were more likely to be positive for HCV, suggesting both the
duration and the frequency of detention to be relevant aspects for
the risk of acquiring this infection. Self-reported in-detention risk
behaviours, such as injecting drug use and having a non-
professional tattoo or piercing, could only partially explain the
higher probability of positive HCV status among those with
detention experience.
An important strength of this analysis is that it considered the
duration and frequency of detention simultaneously, thus allowing
the independent effects of both aspects to be observed. The total
time spent in detention was clearly associated with the likelihood
of being HCV-positive in this sample. As the time spent in
detention increases, so does the probability of having injected
drugs or having a non-professional tattoo or piercing done at some
point during detention (Koulierakis et al., 2000). Both of these
practices are known routes of HCV transmission, and injecting drug
use in particular is thought to be the main driver of intramural
spread of HCV (Butler et al., 2004; Vescio et al., 2008; Kinner et al.,
2012).
Not all detained PWID inject drugs during their detention, but
studies have shown that those who do are more likely to share
injecting equipment than are PWID in the community (Dolan et al.,
2010; Shewan et al., 1994), thereby increasing their risk of HCVinfection. In the present study, it was found that the practice of
either of these risk behaviours became more likely with increasing
detention experience. It was also possible to show that these two
behaviours partly explain the detention-associated risk of HCV,
supporting the idea of intramural transmission. This finding,
together with the increase in risk associated with detention
frequency, also suggests that the increased risk of HCV among ever-
detainees is not only caused by risk factors inside the detention
facilities, but that further risks are contained in the broader process
of detention.
This hypothesis is also proposed in a paper by Stone et al.,
based on a modelling exercise of the impact of incarceration on
HCV transmission among PWID in Scotland (Stone et al., 2017). As
each detention episode, regardless of duration, entails a transition
of the individual from the community into custody and back
again, the additional risk may arise from these transitions. A
transition in either direction may lead to interruption of opioid
substitution therapy (OST) for individuals in treatment, as specific
arrangements for treatment continuation are often not in place
and OST is not available in all detention facilities in Germany
(Schulte et al., 2017). In detention facilities that do offer OST, a
short sentence is sometimes applied as an exclusion criterion for
OST access (Schulte et al., 2009). Both community- and prison-
based OST have been shown to reduce injecting frequency and
syringe sharing, whereas a cessation of OST results in relapse and
risky behaviour being more likely (Platt et al., 2017; Hedrich et al.,
2012). In an Australian prospective cohort study of male heroin
users, Dolan et al. found that particularly those serving short
prison sentences (<2 months) were likely to drop out of OST,
which increased their risk of HCV seroconversion (Dolan et al.,
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network, and dealing with emotions regarding the recent
detention may all possibly make unsafe use during the first
period in detention more likely.
The first period upon release may also make risk-taking more
likely, as this can be a particularly chaotic time for PWID, with
housing and financial arrangements often lacking. In Germany,
health care in prison is covered by a separate prison health system,
and when released, the transfer of the detainee back into the
regular health insurance system should occur seamlessly. Howev-
er, due to bureaucratic barriers this transfer is often delayed,
leaving the newly released individual uninsured and without
access to OST and other health care services immediately upon
release. In addition, there may also be an aspect of ‘celebration’
following release, which may include more risky behaviour. A
Canadian study observed that individuals recently released from
prison reported syringe sharing more frequently than those
without recent prison experience (Milloy et al., 2009). Overall,
cycling between community and custody may increase the risk of
HCV infection through less continuity and more interruptions of
OST and access to other harm reduction measures.
Limitations
This study has several limitations. Due to the way the data
were collected, it was not possible to analyse the different
detention forms separately (juvenile arrest/prison, pre-trial
custody, prison, forensic commitment). The effects of frequency
and duration may vary between these forms, but it was not
possible to account for this in the analysis. Data on access and
utilization of OST and other harm reduction services during
detention episodes and transition periods were not collected and
it was therefore not possible to investigate the effect of these on
the risk of acquiring HCV. Data on further intramural risk factors
(e.g., sharing of snorting tubes, razors, bloody fights, etc.) were
also not collected and could not be corrected for in the second
multivariable model. It is also possible that not all participants
answered the question on injecting drug use in prison truthfully
due to social desirability. Finally, the possibility that individuals
with a higher HCV risk behaviour in the community are also more
likely to be detained could not be excluded; e.g. with an
increasing severity of addiction, both the injection frequency
and the likelihood of drug-related crime, in order to support the
addiction, may increase.
Conclusions and recommendations
Efforts are needed to improve the prevention of HCV
transmission occurring throughout the detention process. Preven-
tion measures such as needle and syringe exchange programmes
and evidence-based drug dependence treatment, including OST,
are known to reduce the risk of transmission of blood-borne
viruses and are broadly used in the community. On the basis of the
equivalence of care principle, these effective measures of preven-
tion should also be made available to PWID in all German detention
facilities. Further research is needed, particularly in order to better
understand the risk increase associated with the transitions
between detention and the community. A cohort study of PWID
entering a detention facility, including a follow-up period upon
release, would improve our understanding of the risks of
contracting HCV and other blood-borne viruses that PWID in
Germany are potentially exposed to throughout the process of
detention, including the period post release. It would also allow the
impact of successfully maintained or interrupted OST on the risk of
infection to be estimated.Furthermore, considering the high HCV prevalence observed
among the participants with detention experience, detention
facilities offer an important opportunity to counsel, test, and treat
PWID. Opt-out HCV screening should be offered upon entry and
thereafter on a regular basis, with a positive test result leading to
treatment while in detention. Appropriate linkage to care upon
release must also be provided in order to make sure that the
patients can progress through the continuum of care, regardless of
whether they are in custody or in the community. Since the
introduction of the directly acting antivirals, with their high
clearance rates, limited side-effects, and reduced treatment times,
this now appears more feasible than ever.
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